Document Detail

Clopidogrel: a CURE in acute coronary syndromes?
MedLine Citation:
PMID:  11866684     Owner:  NLM     Status:  MEDLINE    
The standard approach to preventing acute coronary syndromes (ACSs)has been to inhibit platelet aggregation with aspirin and to inhibit blood coagulation with low molecular-weight heparin (LMWH). Even with this combination there is still a substantial short and long-term cardiovascular risk. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial [1] compared clopidogrel plus aspirin against aspirin alone in patients with ACSs. The clopidogrel regimen was a loading dose of 300 mg p.o. followed by 75 mg/day and the recommended dose of aspirin was 75 - 325 mg/day. The first primary outcome was a composite of death from cardiovascular causes, non-fatal myocardial infarction (MI) or stroke and this occurred significantly less often in the clopidogrel than the placebo group (9.3 vs. 11.4%). Although there were more clopidogrel patients with life-threatening bleeding (clopidogrel 2.2%, placebo 1.8%), this represented GI haemorrhages and bleeding at sites of arterial puncture rather than fatal bleeding. This trial suggests a role for clopidogrel in the long-term treatment of ACSs.
Sheila A Doggrell
Related Documents :
16682384 - A comparison of dual vs. triple antiplatelet therapy in patients with non-st-segment el...
17067704 - Myocardial infarction complicating the initial phase of an ovarian stimulation protocol.
18651504 - The effect of preoperative aspirin use on postoperative bleeding and perioperative myoc...
12228784 - Randomized double-blind safety study of enoxaparin versus unfractionated heparin in pat...
23689834 - Immediate primary transcatheter closure of left ventricular free wall rupture after myo...
17372814 - The worldwide social burden of atrial fibrillation: what should be done and where do we...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  3     ISSN:  1465-6566     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-02-27     Completed Date:  2002-09-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  351-3     Citation Subset:  IM    
Department of Physiology and Pharmacology, University of Queensland, Brisbane, Queensland 4072, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Aspirin / therapeutic use
Coronary Disease / drug therapy*,  mortality
Double-Blind Method
Hemorrhage / chemically induced
Middle Aged
Myocardial Infarction / drug therapy,  mortality
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Stroke / drug therapy,  mortality
Ticlopidine / administration & dosage,  adverse effects,  analogs & derivatives,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Seretide for obstructive lung disease.
Next Document:  Future developments in assisted reproduction in humans.